ReviewVascular health and risk management2019
Cholesterol-embolization syndrome: current perspectives.
Review in Vascular health and risk management, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 66 citations in OpenAlex.
- Cholesterol embolization syndrome: A case report and literature review.Journal of vascular surgery cases and innovative techniques · 2026Article
- Fulminant cholesterol crystal embolism syndrome triggered by Vein of Marshall ethanol infusion: a case report.BMC cardiovascular disorders · 2026Article
- Neurological Complications After Thoracic Endovascular Repair (TEVAR): A Narrative Review of the Incidence, Mechanisms and Strategies for Prevention and Management.Journal of personalized medicine · 2026Review
- The mystery of the blue toe.Rheumatology and immunology research · 2025Article
- Blue Toe Syndrome as a Rare Complication of Abdominal Aortic Aneurysm: Case Report.Clinical case reports · 2025Article
- Blue Toe Syndrome Responding to Direct Hemoadsorption Therapy with the RheocarnaInternal medicine (Tokyo, Japan) · 2025Article
- Cholesterol crystal embolization syndrome: Systemic and end-organ injury.American heart journal plus : cardiology research and practice · 2025Article
- Cholesterol Embolization Syndrome Presenting with Multifocal Cerebral Infarction After Thoracic Endovascular Aortic Repair: A Case Report.Journal of clinical medicine · 2025Article
- Blue toe syndrome - systemic cholesterol crystal embolism secondary to cardiovascular procedures: a forensic autopsy report of two cases.Forensic science, medicine, and pathology · 2025Article
- Small-vessel vasculitis associated with cholesterol embolism: a case report.BMC rheumatology · 2024Article
- The Controversial Role of Glucocorticoids in Atheroembolic Renal Disease: A Narrative Review.Journal of clinical medicine · 2024Review
- Review
- Approach to the Atypical Wound.American journal of clinical dermatology · 2024Review
- Association between atherosclerosis and the development of multi-organ pathologies.SAGE open medicine · 2024Review
- Article
- Atherosclerosis of the aorta before blue toe syndrome: Spontaneously ruptured aortic plaques revealed by non-obstructive general angioscopy.Journal of cardiology cases · 2023Article
- Acute type B aortic dissection with multiple cholesterol embolism: an autopsy case report.European heart journal. Case reports · 2023Article
- Part I: Cutaneous manifestations of cardiovascular disease.Journal of the American Academy of Dermatology · 2023Review
- Idiopathic cholesterol crystal embolism with atheroembolic renal disease and blue toes syndrome: A case report.World journal of clinical cases · 2022Article
- Anaesthesia for endovascular repair of ruptured abdominal aortic aneurysms.BJA education · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cholesterol-embolization syndrome (CES) is a multisystemic disease with various clinical manifestations. CES is caused by embolization of cholesterol crystals (CCs) from atherosclerotic plaques located in the major arteries, and is induced mostly iatrogenically by interventional and surgical procedures; however, it may also occur spontaneously. Embolized CCs lead to both ischemic and inflammatory damage to the target organ. Therefore, anti-inflammatory agents, such as corticosteroids and cyclophosphamide, have been investigated as treatment for CES in several studies, with conflicting results. Recent research has revealed that CES is actually a kind of autoinflammatory disease in which inflammasome pathways, such as NLRP3 and IL1, are induced by CCs. These recent findings may have clinical implications such that colchicine and IL1 inhibitors, namely canakinumab, may be beneficial in the early stages of CES.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.